Capricor Therapeutics (NASDAQ:CAPR) Stock Crosses Below Two Hundred Day Moving Average of $4.81

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.81 and traded as low as $4.63. Capricor Therapeutics shares last traded at $5.03, with a volume of 292,480 shares traded.

Capricor Therapeutics Stock Up 10.5 %

The firm has a market cap of $126.96 million, a price-to-earnings ratio of -4.45 and a beta of 4.09. The company has a 50-day moving average price of $4.10 and a 200 day moving average price of $4.81.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its holdings in shares of Capricor Therapeutics by 93.2% during the fourth quarter. Millennium Management LLC now owns 52,728 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 25,440 shares in the last quarter. Morgan Stanley raised its holdings in Capricor Therapeutics by 7.4% during the fourth quarter. Morgan Stanley now owns 42,652 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 2,950 shares in the last quarter. Marshall Wace LLP bought a new position in Capricor Therapeutics during the fourth quarter valued at about $109,000. Renaissance Technologies LLC raised its holdings in Capricor Therapeutics by 125.7% during the fourth quarter. Renaissance Technologies LLC now owns 23,021 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 12,821 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Capricor Therapeutics by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 226,110 shares of the biotechnology company’s stock valued at $872,000 after buying an additional 4,077 shares in the last quarter. 11.06% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

(Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.